Caribou Biosciences Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
CRBU$0.41-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| March 31,2024 | December 31,2023 | |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $49,400 | $51,162 |
| Marketable securities, short-term | 244,588 | 277,665 |
| Accounts receivable | 917 | 148 |
| Contract assets | 971 | 1,425 |
| Other receivables | 1,725 | 2,286 |
| Prepaid expenses and other current assets | 6,913 | 6,155 |
| Total current assets | 304,514 | 338,841 |
| NON-CURRENT ASSETS | ||
| Investments in equity securities | 7,753 | 7,753 |
| Marketable securities, long-term | 51,938 | 43,577 |
| Property and equipment, net | 19,167 | 18,270 |
| Operating lease, right of use assets | 21,659 | 22,182 |
| Other assets | 1,794 | 1,586 |
| TOTAL ASSETS | $406,825 | $432,209 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $5,940 | $3,120 |
| Accrued expenses and other current liabilities | 18,990 | 21,135 |
| Operating lease liabilities, current | 1,264 | 1,200 |
| Deferred revenue ($2,487 and $2,487 from related party, respectively) | 2,827 | 2,847 |
| Total current liabilities | 29,021 | 28,302 |
| LONG-TERM LIABILITIES | ||
| Deferred revenue, net of current portion ($3,108 and $3,730 from related party, respectively) | 5,428 | 6,102 |
| MSKCC success payments liability | 2,636 | 2,939 |
| Operating lease liabilities, non-current | 25,895 | 25,908 |
| Deferred tax liabilities | 556 | 557 |
| Total liabilities | 63,536 | 63,808 |
| COMMITMENTS AND CONTINGENCIES (Note 9) | ||
| STOCKHOLDERS’ EQUITY | ||
| Common stock, par value $0.0001 per share, 300,000,000 shares authorized at March 31, 2024, and December 31, 2023, respectively; 90,314,501 and 88,448,948 shares issued and outstanding as of March 31, 2024, and December 31, 2023, respectively | 9 | 8 |
| Additional paid-in-capital | 684,121 | 667,648 |
| Accumulated other comprehensive (loss) income | (322) | 30 |
| Accumulated deficit | (340,519) | (299,285) |
| Total stockholders’ equity | 343,289 | 368,401 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $406,825 | $432,209 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.